November 22nd 2024
The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Prostate Cancer Screening: "Yes, No, or Maybe?"
March 18th 2015The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press, but, Leonard G. Gomella, MD, told attendees at the 8th International Prostate Cancer Congress, the decision to screen or not to screen boiled down to "using common sense, shared decision making, and choosing the right patients to screen."
For Some With Intermediate-Risk Prostate Cancer, Active Surveillance May Not Be Enough
February 23rd 2015The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients, according to results of a new study, the first to examine long-term outcomes of patients with low- versus intermediate-risk prostate cancer who have been managed with this conservative approach to care.
Prostate Cancer Foundation Partners with Movember Foundation
October 28th 2014The Prostate Cancer Foundation (PCF) announced that the partnership with the Movember Foundation has resulted in 7 new Challenge Awards for 2014. In May, it was announced that PCF received over $8.4 million from the Movember Foundation, the leading global organization committed to changing the face of men's health.
Fall Patient Insight Webinars from the Bladder Cancer Advocacy Network
October 20th 2014The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:
For Men With Prostate Cancer, Vessel-Sparing Radiation Can Preserve Sexual Function
September 17th 2014With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option
No Matter Who You Are, Get Checked!
July 23rd 2014It happens all the time. A man gets older, but he doesn't think he needs to be checked for prostate cancer. Even if his father or grandfather had prostate cancer, he feels fine, and does not see the need for yearly physical exams. However, the reality is that 1 in 7 American men will be diagnosed with prostate cancer at some point in his lifetime.
Pamela Devine Discusses Psychosocial Issues Concerning Men with Prostate Cancer
July 16th 2014Pamela Devine, RN, clinical nurse specialist, Philadelphia Veterans Administration Medical Center, discusses some of the psychosocial issues that men face when they are receiving treatment for their prostate cancer.
Managing Side Effects of Androgen-Deprivation Therapy Increasingly Important
July 9th 2014Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists and oncology practitioners in collaboration with primary care physicians.